← All trials
NCT04431999
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2020
- Primary completion
- Sep 30, 2022
- Completion date
- Aug 31, 2023
- First posted
- Jun 16, 2020
- Last posted
- Jun 16, 2020
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Direction Centrale du Service de Santé des ArméesLead sponsor
- FloralisCollaborator
- TIMC-IMAGCollaborator
- Direction Centrale du Service de Santé des ArméesStudy director
- Direction Centrale du Service de Santé des ArméesOverall official - principal investigator
- Ecoles militaires de santé de Lyon-BronOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.